Late-onset right ventricular failure in patients with preoperative small left ventricle after implantation of continuous flow left ventricular assist device
2014 (English)In: Circulation Journal, ISSN 1346-9843, E-ISSN 1347-4820, Vol. 78, no 3, 625-633 p.Article in journal (Refereed) Published
Background: The continuous flow (CF) left ventricular assist device (LVAD) has replaced the pulsatile flow (PF) LVAD because of its advantages of better patient survival and higher quality of life. However, "late-onset right ventricular failure (RVF)" after CF LVAD implantation has emerged as an increasing concern, but little is known about the mechanism. Methods and Results: We retrospectively analyzed the 3-month hemodynamic and echocardiographic data from 38 consecutive patients who had received CF LVADs, and from 22 patients who had received PF LVADs. Late-onset RVF was defined as persistent right ventricular stroke work index (RVSWI) less than4.0 g/m(2) at any rotation speed and after saline infusion test at 5 weeks after implantation of CF LVAD. Patients with late-onset RVF had significantly impaired exercise tolerance indicated by shorter 6-min walking distance and lower peak (V) over dot O-2, and worsened tricuspid regurgitation, together with enlargement of the RV under CF LVAD treatment (all Pless than0.05). Univariable analyses demonstrated that preoperative smaller LV diastolic diameter (LVDd) was the risk factor for late-onset RVF with a cutoff value of 64 mm calculated by ROC analysis (area under curve, 0.925). In contrast, there was no correlation between preoperative LVDd and postoperative RVSWI in the PF LVAD group, though their preoperative background was worse than that of the CF group. Conclusions: In the setting of preoperative small LVDd, CF LVAD may cause late-onset RVF by leftward shift of the interventricular septum.
Place, publisher, year, edition, pages
Japanese Circulation Society , 2014. Vol. 78, no 3, 625-633 p.
Heart failure; Interventricular septum; Stroke work index; Survival
IdentifiersURN: urn:nbn:se:liu:diva-111177DOI: 10.1253/circj.CJ-13-1201ISI: 000332141100017PubMedID: 24430596OAI: oai:DiVA.org:liu-111177DiVA: diva2:754545
Funding Agencies|Fukuda Foundation for Medical Technology; Japanese Heart Foundation; Pfizer Health Research Foundation; Japan Society for the Promotion of Science 2014-10-102014-10-102014-10-21Bibliographically approved